A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

2012 ◽  
Vol 48 (2) ◽  
pp. 196-201 ◽  
Author(s):  
Jun Ho Yi ◽  
Sumitra Thongprasert ◽  
Jeeyun Lee ◽  
D.C. Doval ◽  
Se Hoon Park ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Biliary Tract Carcinoma ◽  
Multinational Study ◽  
Line Treatment ◽  
Second Line

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e14653-e14653 ◽  
Author(s):  
J. Yi ◽  
S. Thongprasert ◽  
D. Doval ◽  
J. Lee ◽  
M. N. Cho ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Biliary Tract Carcinoma ◽  
Multinational Study ◽  
Line Treatment ◽  
Second Line

scholarly journals Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer

2018 ◽  
Vol 29 ◽  
pp. viii259
Author(s):  
J.S. Yoon ◽  
K.-H. Lee ◽  
G.J. Cheon ◽  
Y.-J. Bang ◽  
D.-Y. Oh
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Tract Cancer

Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study

Onkologie ◽  
2011 ◽  
Vol 34 (8) ◽  
pp. 469-470 ◽  
Author(s):  
Annekathrin Roth ◽  
Eberhard Schleyer ◽  
Konrad Schoppmeyer ◽  
Regine Kluge ◽  
Christian Wittekind ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Tract Cancer

Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer

2017 ◽  
Vol 80 (6) ◽  
pp. 1189-1196 ◽  
Author(s):  
Satoshi Kobayashi ◽  
Makoto Ueno ◽  
Kazuya Sugimori ◽  
Chigusa Morizane ◽  
Yasushi Kojima ◽  
...  
Keyword(s):  
Dose Rate ◽  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Fixed Dose ◽  
Line Treatment ◽  
Second Line ◽  
Tract Cancer ◽  
Fixed Dose Rate

Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature

2019 ◽  
Vol 63 (4) ◽  
Author(s):  
Salvatore Grisanti ◽  
Vittorio D. Ferrari ◽  
Michela Buglione ◽  
Giorgio M. Agazzi ◽  
Roberto Liserre ◽  
...  
Keyword(s):  
Systematic Review ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Glioblastoma ◽  
Line Treatment ◽  
Second Line ◽  
Review Of Literature

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group

2011 ◽  
Vol 102 (6) ◽  
pp. 1171-1175 ◽  
Author(s):  
Hiroshi Kitamura ◽  
Keisuke Taguchi ◽  
Yasuharu Kunishima ◽  
Masahiro Yanase ◽  
Atsushi Takahashi ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
Second Line ◽  
Metastatic Urothelial Carcinoma

scholarly journals Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

ESMO Open ◽  
2022 ◽  
Vol 7 (1) ◽  
pp. 100314
Author(s):  
M.M. Javle ◽  
D.-Y. Oh ◽  
M. Ikeda ◽  
W.-P. Yong ◽  
K. Hsu ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Second Line ◽  
Tract Cancer ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document